OAA DUO
Occipital and upper cervical application zones, formulated for the cranial dermatome transition.
A two-step topical concept designed around the occipital application area, where cranial and cervical dermatomes meet.
Label QR
Opens the public information page in the reader's language.
https://www.siriamlab.com/qr/oaa-duo
Open patient pageComplete scientific monograph: anatomy, formulation architecture, references and revision record.
Chapter 01
Product identity
Identification, classification, family, intended use, anatomical region and the documents this record is governed by.
Identification of the record: product identifier, classification, family, intended use, anatomical region and the controlled documents it is governed by.
Documentation metadata+
Chapter 01 — related anatomy
Related documents
Future references
- GTIN / label identifierReservedCommercial identifier reserved for the published label.
Record identification
- Product ID
- SIR-OAA-01
- Family
- OAA DUO
- Region
- Cranial — occipito-atlanto-axial field
- Last update
- 2026-02
Handbook source
Neurodermal modulation of OAA (C0–C2) with a clear EMG response.
- Phase 1: afferent damping
- Phase 2: integration and stabilisation
- Developer
- MT DO, DCP
- Pharmacist
- AVA
- Chapter version
- 1.0
- Product ID
- SIR-OAA-01
The handbook is the scientific master. Every statement rendered on this record originates from this chapter; the platform never creates independent scientific content.
Chapter 02
Executive summary
The record in short: professional summary, patient summary and the sequential treatment model behind it.
The record read in short: professional summary, patient summary and the sequential treatment model behind the formulation.
Documentation metadata+
Chapter 02 — related anatomy
Declared; content in preparation.
Related documents
Future references
- TranslationsReservedExecutive summary in Dutch, French and German.
Executive summary
The reading entry of the record: what the composition is for, in professional and in patient language.
Purpose
OAA DUO exists to give practitioners a clearly delimited application field at the occipital transition, with a two-step texture sequence that supports consistent, reproducible routines.
Clinical goal
Primary anatomical region
occipital
Primary therapeutic objective
Documented cutaneous topical composition for the suboccipital, retroauricular, submandibular and pre-SCM application field.
Professional summary
OAA DUO is documented as a cutaneous topical composition for the head application field. This summary is maintained by the documentation team and updated with each revision of the record.
Patient summary
Occipital and upper cervical application zones, formulated for the cranial dermatome transition.
Keywords
Chapter 03
Anatomy snapshot
The anatomical region of the record and every structure of its application field, resolving into the Neuro Atlas.
The anatomical identity of the record: the region, the segmental levels and the surface territory the formulation is documented for.
Documentation metadata+
Chapter 03 — related anatomy
Related documents
Future references
- 3D Atlas referenceReservedVolumetric reference of the field, prepared for the atlas engine.
- EMG referenceReservedFunctional EMG dataset linked to the segmental levels of this record.
- SRST referenceReservedSegmental reflex surface topography mapping.
Snapshot
Anatomy snapshot
Six metameric expressions per segment — dermatome, myotome, sclerotome, viscerotome, micro-angiotome and neurotome. Individual structures inside an expression open their own illustration plate.
Application zones
Anatomy
Anatomical overview
The application field of OAA DUO is described through its dermatomes, peripheral nerves, plexus relations and metameric levels. Each object below resolves to the corresponding structure in the Neuro Atlas.
- HeadCranial and occipital surface territories, innervated by branches of the trigeminal and upper cervical nerves.Body regionAtlas →
- 2 dermatomes · 4 metamersSegmental objects linked to this record.Segmental scope
- 3 peripheral nervesSurface territories referenced by the application field.Peripheral scope
Segmental
Dermatomes
Segmental
Peripheral nerves
- Greater occipital nervePosterior scalp from the superior nuchal line toward the vertex.Peripheral nerveAtlas →
- Lesser occipital nerveLateral occipital scalp and superior auricular surface.Peripheral nerveAtlas →
- Third occipital nerveSuboccipital surface and upper cervical midline.Peripheral nerveAtlas →
Segmental
Plexus relations
Segmental
Metamers
Professional mode
Segmental links are protected.
Metameric cross-references are reserved for practitioners trained in segmental reasoning. Enter your professional code to continue.
Segmental
Neurocutaneous regions
Anatomical identity
Primary region
Dermatomes
Peripheral nerves
Plexus
Metamers
Neurocutaneous territories
Body regions
Surface anatomy
- 3D Atlas referenceReservedVolumetric field reference.
- EMG referenceReservedFunctional EMG dataset.
- SRST referenceReservedSegmental reflex surface topography.
Chapter 04
Clinical purpose
Objective, strategy, workflow and the boundaries within which this record is documented.
The clinical objective of the record, its rationale, and the boundaries within which it is documented.
Documentation metadata+
Chapter 04 — related anatomy
Related documents
Future references
- Evidence levelReservedGraded evidence classification per documented statement.
- Clinical casesReservedStructured practitioner observations linked to this record.
Purpose
Why this formulation exists
OAA DUO is documented as a cutaneous topical composition for the head application field. This summary is maintained by the documentation team and updated with each revision of the record.
Why this record exists
OAA DUO exists to give practitioners a clearly delimited application field at the occipital transition, with a two-step texture sequence that supports consistent, reproducible routines.
Neurocutaneous region it was designed for
Occipital neurocutaneous zone
Anatomical interface it addresses
Cranial and occipital surface territories, innervated by branches of the trigeminal and upper cervical nerves.
Clinical philosophy
The occipital field is supplied predominantly by the dorsal ramus of C2 and by C2–C3 contributions travelling with the lesser occipital nerve. This convergence of cranial and cervical territories makes the region anatomically distinctive and well suited to a dedicated surface concept.
- Cutaneous topical composition; the application field is defined by the treating professional.
- Application is documented per session so routines remain comparable over time.
Chapter 05
Application protocol
Timeline, application sites, professional and patient instructions, safety and storage.
Phases, cadence, duration, zone order and the documented application sequence, with practitioner and patient notes.
Documentation metadata+
Chapter 05 — related anatomy
Related documents
Future references
- Printable protocolReservedPrint-ready protocol sheet generated from this record.
Surface
Application zones
The zones listed are possible application locations. The practitioner identifies the exact spot within these possibilities using the SRST (Segmental Reflex Sensitisation Test). Future evaluation will use EMG before and after application.
Suboccipital
Detailed application guidance is in preparation.
Application fieldRetroauricular
Detailed application guidance is in preparation.
Application fieldSubmandibular
Detailed application guidance is in preparation.
Application fieldPre-SCM
Detailed application guidance is in preparation.
Application field
Protocol
Application protocol
Phase 1
Neurodermal release
Week 1–2 · 1–2 applications per day
Until phase 2 is introduced
The first texture is applied thinly on the target zone within the possible application zones, in the official zone order: suboccipital, directly below the hairline; retroauricular, behind the ear; submandibular, from the angle of the mandible towards the chin; and pre-SCM, immediately anterior to the upper portion of the sternocleidomastoid. Zone order stays identical at every session.
SuboccipitalRetroauricularSubmandibularPre-SCMPhase 2
Neurodermal integration
Week 3 evening · from week 4 morning and evening
Until the product is finished
From week 3 phase 2 is added in the evening: phase 1 in the morning on the target zone, phase 2 in the evening on that same target zone. From week 4 — or once phase 1 is finished and phase 2 is also recommended by your therapist — phase 2 is applied on the target zone in the morning and in the evening until the product is finished.
SuboccipitalRetroauricularSubmandibularPre-SCMMaintenance
Continued routine
1–3 sessions per week
Ongoing, reviewed periodically
The sequence is continued at a reduced cadence. Frequency, zones and observations are recorded in the professional log sheet and reviewed at agreed intervals.
SuboccipitalRetroauricularSubmandibularPre-SCM
Zone sequence
- 01Suboccipital
- 02Retroauricular
- 03Submandibular
- 04Pre-SCM
- 01Cleanse and dry the four defined application zones.
- 02Apply step one thinly in the order suboccipital → retroauricular → submandibular → pre-SCM.
- 03Allow two minutes before applying step two over the identical zones.
- 04Use as agreed with your healthcare professional.
Region definition
The four official zones are delimited: suboccipital directly below the hairline, retroauricular behind the ear, submandibular from the angle of the mandible towards the chin, and pre-SCM immediately anterior to the upper sternocleidomastoid.
Sequence
Step one, pause, step two — kept identical across sessions for comparability.
Documentation
Frequency and duration are recorded in the professional log sheet.
OAA protocol (definitive)
Zones
- Pre-auricular
- Mandible
- Temporal
- Retroauricular
Week 1–2
OAA-1 (1–2× per day)
Week 3
Morning: OAA-2 · Evening: OAA-1
Week 4
OAA-2 (1–2× per day)
Week 5
OAA-2 (evening)
On relapse: reintroduce OAA-1 for 3 days.
Chapter 06
Formulation science
The scientific philosophy of the composition: sequential formulation, phase relationship and ingredient rationale.
The composition read as an architecture, with the current formula held read-only and any proposed successor documented alongside it.
Documentation metadata+
Chapter 06 — related anatomy
Declared; content in preparation.
Related documents
Future references
- Ingredient linksReservedEvery constituent resolving to its RM-001 entry.
- Version comparisonReservedSide-by-side comparison of current and proposed composition.
Composition
Formulation architecture
The composition is documented as a map rather than a list. Every constituent is recorded with the function it carries, the reason it is present in this field, how it relates to the rest of the composition and the cutaneous topical formulation category it belongs to.
- 01Aqua base
Aqua
Carrier system
- Functional role
- Carrier phase
- Formulation purpose
- Sets the water phase that determines spreadability across a defined surface field.
- Interaction within the composition
- Holds the humectant fraction in solution and carries the emulsified lipid phase evenly over the zone.
- 02Glycerin
Glycerin
Humectant
- Functional role
- Moisture binding
- Formulation purpose
- Keeps the applied layer supple so the same field can be worked repeatedly without dryness on the skin surface.
- Interaction within the composition
- Balances the emollient fraction: the humectant governs the water phase, the emollient the lipid phase.
- 03Shea butter
Butyrospermum parkii butter
Emollient
- Functional role
- Skin-feel and occlusive body
- Formulation purpose
- Gives the texture enough body to stay on the applied zone rather than running along the hairline.
- Interaction within the composition
- Carries the lipid-soluble antioxidant fraction and slows the evaporation of the water phase.
- 04Panthenol
Panthenol
Conditioning agent
- Functional role
- Surface conditioning
- Formulation purpose
- Documented as a conditioning constituent of the cutaneous topical base; contributes to a smooth, non-tacky finish.
- Interaction within the composition
- Water-soluble; works alongside glycerin in the same phase without altering the emulsion.
- 05Tocopherol
Tocopherol
Antioxidant stabiliser
- Functional role
- Formulation stability
- Formulation purpose
- Protects the lipid fraction over the shelf life of the record so successive batches stay comparable.
- Interaction within the composition
- Dissolved in the shea fraction; stabilises the constituents it is dispersed in rather than acting on the skin.
- 06MSM
Dimethyl sulfone
Sulphur constituent
- Functional role
- Documented constituent of both phases
- Formulation purpose
- Documented constituent of phase 1 and phase 2 of the OAA record; kept at a low level so the texture of both steps stays light and spreadable.
- Interaction within the composition
- Dispersed in a small amount of jojoba before it enters the base, which keeps the powder evenly distributed through the cream.
- 07Rosemary leaf extract
Rosmarinus officinalis leaf extract
Botanical extract
- Functional role
- Aromatic and antioxidant fraction
- Formulation purpose
- Gives phase 1 its recognisable aromatic signature, which practitioners use to distinguish the two textures during a session.
- Interaction within the composition
- Lipid-affine; stabilised by tocopherol and dispersed through the shea fraction.
- 08Magnesium chloride
Magnesium chloride
Mineral salt
- Functional role
- Water-phase mineral constituent
- Formulation purpose
- Documented constituent of the phase 2 water phase; contributes to the lighter, faster-absorbing texture of the integration step.
- Interaction within the composition
- Kept in the aqueous fraction with glycerin; the emulsion is balanced so the salt load does not destabilise the lipid phase.
Reading the map
Constituents are grouped by formulation category: a carrier system that governs spread, a water phase that governs feel, a lipid phase that governs stay-time, and stabilising constituents that keep successive batches comparable. Interactions describe the composition only; no physiological effect is asserted.
Cutaneous topical formulation rationale
The formulation is built for reproducible application on the documented zones: a texture that spreads thinly, a controlled sensory profile and a composition suitable for repeated professional use.
Representative composition overview. The full INCI listing is published in the composition index.
Philosophy
Formulation philosophy
The record is built around one field and two textures. Phase 1 carries the aromatic, lipid-affine fraction and is applied first across the four official zones; phase 2 is a lighter aqueous texture applied over the identical zones to close the sequence. Splitting the composition in two keeps each texture simple, makes the sequence reproducible between practitioners, and lets the same field be documented step by step. The record documents composition and application only; no physiological or therapeutic mechanism is claimed.
The occipital field is supplied predominantly by the dorsal ramus of C2 and by C2–C3 contributions travelling with the lesser occipital nerve. This convergence of cranial and cervical territories makes the region anatomically distinctive and well suited to a dedicated surface concept.
Chapter 07
Product formula
Linked document PF-001. The formulation master: phase formulas, ingredient records, suppliers and the current → proposed comparison.
Linked document PF — the formulation master. Ingredient data exists once, in the product formula record, and is referenced from here.
Documentation metadata+
Chapter 07 — related anatomy
Declared; content in preparation.
Related documents
Future references
- Ingredient linksReservedEvery constituent resolving to its RM-001 entry.
- Version comparisonReservedSide-by-side comparison of current and proposed composition.
OAA DUO — Product Formula record
- Document
- PF-001
- Version
- 1.0
- Revision date
- 2026-02
- Basis
- Lanette protocol, two sequential phases of 100 g.
Phase 1 — Neuro afferent damping
- Intent
- Afferent damping.
- Batch size
- 100 g
- Filling
- 6 jars of 15 ml (×2)
Ingredient table — as approved in the handbook
| Ingredient | Source | Quantity | Remark |
|---|---|---|---|
| Lanette cream | — | 66 g | Top up to 100 ml if insufficient after all additions. |
| Aqua purificata | — | 18 g | — |
| Magnesium chloride | — | 4 g | Above 5% irritation. |
| MSM | — | 2.5 g | Disperse in a little jojoba. Above 3% texture problem. |
| PEA | Vitals | 2 g (5 capsules) | Disperse in a little jojoba. Above 3% saturation. |
| Ginkgo biloba | Matisson | 1 g (8 capsules) | — |
| Boswellia serrata | WeightWorld | 2 softgels | — |
| Copaiba | Aroma Zone | 0.3 ml | — |
| Blue Lotus | — | 1 drop per 300 g preparation | — |
| Melissa officinalis | Soria Natural | 1 ml | — |
| Gelsemium (drops 30C) | — | 0.5 ml | Whole. |
| Silicea Gel (+ 1 drop Silicea D8) | — | 5 g | Belongs to the water phase. |
| COSGARD | — | 0.7 g | — |
Phase 2 — Regenerative integration
- Intent
- Integration and stabilisation.
- Batch size
- 100 g
- Filling
- —
Ingredient table — as approved in the handbook
| Ingredient | Source | Quantity | Remark |
|---|---|---|---|
| Lanette cream | — | 68 g | — |
| Aqua purificata | — | 16 g | — |
| D-Panthenol | NH | 2 g | — |
| Niacinamide powder | — | 1.5 g | — |
| Ginkgo biloba | Matisson | 0.7 g | — |
| MSM (dry) | — | 1.5 g | Disperse in a little jojoba. |
| Q10 | — | 0.5 g | Disperse in a little jojoba. |
| Vitamin E | — | 0.5 g | — |
| Boswellia (softgel) + frankincense drop | — | 0.5 g | — |
| Copaiba | — | 0.3 g | — |
| Blue Lotus | — | 1 drop per 300 g preparation | — |
| Silicea Gel (+ drop Silicea D8) | — | 3 g | — |
| COSGARD | — | 0.7 g | — |
Ingredient cards — OAA-1
Lanette cream
66 g
Source
Not declared in the handbook
Top up to 100 ml if insufficient after all additions.
Aqua purificata
18 g
Source
Not declared in the handbook
Magnesium chloride
4 g
Source
Not declared in the handbook
Above 5% irritation.
MSM
2.5 g
Source
Not declared in the handbook
Disperse in a little jojoba. Above 3% texture problem.
PEA
2 g (5 capsules)
Source
Vitals
Disperse in a little jojoba. Above 3% saturation.
Ginkgo biloba
1 g (8 capsules)
Source
Matisson
Boswellia serrata
2 softgels
Source
WeightWorld
Copaiba
0.3 ml
Source
Aroma Zone
Blue Lotus
1 drop per 300 g preparation
Source
Not declared in the handbook
Melissa officinalis
1 ml
Source
Soria Natural
Gelsemium (drops 30C)
0.5 ml
Source
Not declared in the handbook
Whole.
Silicea Gel (+ 1 drop Silicea D8)
5 g
Source
Not declared in the handbook
Belongs to the water phase.
COSGARD
0.7 g
Source
Not declared in the handbook
Ingredient cards — OAA-2
Lanette cream
68 g
Source
Not declared in the handbook
Aqua purificata
16 g
Source
Not declared in the handbook
D-Panthenol
2 g
Source
NH
Niacinamide powder
1.5 g
Source
Not declared in the handbook
Ginkgo biloba
0.7 g
Source
Matisson
MSM (dry)
1.5 g
Source
Not declared in the handbook
Disperse in a little jojoba.
Q10
0.5 g
Source
Not declared in the handbook
Disperse in a little jojoba.
Vitamin E
0.5 g
Source
Not declared in the handbook
Boswellia (softgel) + frankincense drop
0.5 g
Source
Not declared in the handbook
Copaiba
0.3 g
Source
Not declared in the handbook
Blue Lotus
1 drop per 300 g preparation
Source
Not declared in the handbook
Silicea Gel (+ drop Silicea D8)
3 g
Source
Not declared in the handbook
COSGARD
0.7 g
Source
Not declared in the handbook
Supplier links
Sources named in the handbook. Qualification and specifications are held in the approved raw-material manual; this record shows the relationship only.
- Vitals
- Matisson
- WeightWorld
- Aroma Zone
- Soria Natural
- NH
Current → proposed
| Field | Current | Proposed |
|---|---|---|
| Formula version | PF-001 v1.0 — approved | Reserved — no successor issued |
| Ingredient table | Phase 1 and phase 2 as approved in HB-OAA | Reserved — change request required (RM-008) |
Chapter 08
Standard operating procedure
Linked document SOP-001. The manufacturing master: workflow, equipment, quality control, packaging, traceability and release criteria.
Linked document SOP — the manufacturing master. Process, equipment, quality control, packaging and traceability.
Documentation metadata+
Chapter 08 — related anatomy
Declared; content in preparation.
Related documents
Future references
- Batch recordsReservedExecuted batch documentation linked to each manufactured lot.
- Deviation managementReservedRegistered deviations and corrective actions.
OAA DUO — manufacturing record (Lanette protocol)
- Document
- SOP-001
- Version
- 1.0
- Revision date
- 2026-02
Manufacturing timeline
- 01Weigh Lanette cream and aqua purificata separately and heat both to ±60 °C.
- 02Dissolve magnesium chloride, niacinamide and panthenol completely in the water phase under gentle stirring.
- 03Separately mix PEA, MSM, Q10, Boswellia and vitamin E with a small amount of jojoba oil into a smooth dispersion.
- 04Add the warm water phase slowly to the Lanette base under continuous homogeneous stirring.
- 05Then add the jojoba actives mix to the emulsion at ±40 °C and mix until fully distributed.
- 06Add the Ginkgo biloba powder capsules gradually and disperse carefully without lumps.
- 07Let the emulsion cool below 35 °C before adding sensitive components.
- 08Add Copaiba, Blue Lotus, Gelsemium Homaccord and Silicea Gel (+ D8 if applicable) and COSGARD 221 and homogenise gently for 1–2 minutes.
- 09Check pH (5.2–5.5), fill into airless dispensers and let stabilise for 24 hours before use.
Quality control
- pH range
- 5.2 – 5.5
- Process temperature
- ±60 °C water phase, ±40 °C actives
- Sensitive additions
- Below 35 °C
- Maximum temperature
- Avoid >70 °C
- Homogenisation
- Gentle, 1–2 minutes
- Stabilisation
- 24 hours before use
Critical checklist
- ✔No lumps (PEA/MSM).
- ✔Homogeneous texture.
- ✔No overheating (avoid >70 °C).
- ✔Correct viscosity (airless compatible).
Equipment
- Balance for separate weighing of base and water phase
- Heating bath / plate to ±60 °C
- Stirring equipment for continuous homogeneous mixing
- Homogeniser for the final 1–2 minute cycle
- pH measurement
- Airless dispensers for filling
Batch structure
- Phase 1 batch
- 100 g — 6 jars of 15 ml (×2)
- Phase 2 batch
- 100 g
- Blue Lotus reference
- 1 drop per 300 g preparation
- Filling
- Airless dispensers
Release criteria
- pH within 5.2 – 5.5.
- Homogeneous texture without lumps.
- Viscosity compatible with airless dispensers.
- 24 hours stabilisation completed before release.
Traceability
- Developer
- MT DO, DCP
- Pharmacist
- AVA
- Manufacturing records
- RM-005 — relationship only
- Quality assurance
- RM-006 — relationship only
Chapter 09
Reference manuals
RM-001 → RM-010. The quality management library this record is connected to, referenced by relationship only.
The reference manual library RM-001 → RM-010, connected to this record by relationship only.
Documentation metadata+
Chapter 09 — related anatomy
Declared; content in preparation.
Related documents
Future references
- Manual publicationReservedReference manuals published as controlled documents.
Documentation hub — reference manuals
RM-001
Ingredient library
Single source for every constituent used in a formulation.
RM-002
Formula matrix
Composition matrix across families and versions.
RM-003
Approved materials
Qualified raw materials and their specifications.
RM-004
Inventory
Material positions, lots and expiry tracking.
RM-005
Manufacturing
Process documentation and manufacturing instructions.
RM-006
Quality assurance
Release checks, deviations and corrective actions.
RM-007
Equipment
Equipment identity, qualification and maintenance.
RM-008
Change control
Governance of proposed versions and their approval.
RM-009
Stability
Stability programme and observation intervals.
RM-010
Clinical outcomes
Structured observation framework for practitioners.
Reference manual integration
- RM-001Ingredient librarySingle source for every constituent used in a formulation.
- RM-002Formula matrixComposition matrix across families and versions.
- RM-003Approved materialsQualified raw materials and their specifications.
- RM-004InventoryMaterial positions, lots and expiry tracking.
- RM-005ManufacturingProcess documentation and manufacturing instructions.
- RM-006Quality assuranceRelease checks, deviations and corrective actions.
- RM-007EquipmentEquipment identity, qualification and maintenance.
- RM-008Change controlGovernance of proposed versions and their approval.
- RM-009StabilityStability programme and observation intervals.
- RM-010Clinical outcomesStructured observation framework for practitioners.
Chapter 10
QR patient information
The label surface, generated from the digital record: what the formulation is, its timeline, application areas, safety and quality assurance.
The label surface of the record, generated from the digital record so patient information can never drift from the documentation.
Documentation metadata+
Chapter 10 — related anatomy
Related documents
Future references
- Printed QRReservedProduction-ready QR code bound to the published version.
Documentation
Downloads
Label
QR resources
Each package carries a QR code that resolves to this documentation record in the reader's language, together with the composition index and the current application protocol. Codes are versioned, so updated documentation reaches practitioners without relabelling.
Resolves to /products/oaa-duo
QR information
- Current QR resolves to
- /products/oaa-duo
- Current version
- 2.1
- Last update
- 2026-02
- Batch number
- OAA-2602
Storage information
Store closed, upright and away from direct sunlight. Storage conditions are documented on the label and repeated here without alteration.
Professional information
Professional reading opens the complete monograph: anatomy, composition architecture, protocol and revision record.
Patient information
Essential reading describes what the composition is, where it is applied and in which order, without clinical interpretation.
- Multilingual QR contentReservedReserved: Dutch, English, French and German resolution of the same record.
Chapter 11
Professional documentation
The controlled document set of this record: references, questions, governance and search metadata.
The document hub of the record. Each document exists once in the controlled set and is referenced from here.
Documentation metadata+
Chapter 11 — related anatomy
Declared; content in preparation.
Related documents
Future references
- Digital signatureReservedSigned approval attached to the published version.
Education
Educational references
- Surface field mapping — method noteLandmark-based definition of application fields.SIRIAM LAB, internal documentation
- Segmental innervation referenceDermatome, nerve and metamer objects used by this record.SIRIAM LAB Neuro Atlas dataset
FAQ
Frequently asked questions
Is this a medicinal product?
No. SIRIAM formulations are cutaneous topical compositions. They are described by application region and composition, not directed at a therapeutic indication but rather at regulation of the nervous system. EMG validation will need to support this further in the future.
Who determines the application region?
The region is identified by a healthcare professional using anatomical landmarks and surface maps. Our documentation supports that conversation.
Can the formulation be combined with other routines?
Combination and sequencing are decided together with the treating professional. We document composition, application and response.
Document hub
Product formula card
Reference manuals
Standard operating procedures
Publications
Handbook placement
- Chapter
- OAA DUO record
- Subchapter
- Anatomy, purpose, protocol, composition, documentation
Scientific sections
Citations
- CitationsReservedFormal citation of this record inside handbook chapters.
Document hierarchy
- HB-OAAHandbook chapter — scientific master
- SDR-001Digital record — presentation source
- PF-001Product formula — formulation master
- INGIngredient cards — derived from the formula
- SUPSupplier links — RM-003 relationship
- SOP-001Manufacturing record
- RMReference manuals — relationships only
- ATLASNeuro Atlas — anatomical relationships
- RESEARCHResearch modules
- QRQR record — patient presentation
Every document carries its own version. Revising the formula does not modify the digital record; revising the manufacturing record does not modify the formula.
Governance of this record
- Responsible author
- SIRIAM LAB documentation team
- Scientific reviewer
- Scientific review board
- Approval status
- Approved
- Release date
- 2026
- Revision date
- 2026-02
- Digital signature
- Reserved
Record metadata
Region
Dermatomes
Peripheral nerves
Plexus
Metamers
Clinical goal
Ingredients
Therapeutic category
Product family
Current version
Documentation
Research
SDR header — product identity
The identification block of the record. Every renderer reads these fields; none of them is restated elsewhere.
Product name
OAA DUO
Product code
OAA
Product family
DUO
Product category
Cutaneous topical composition
Current formula version
2.1
Documentation version
1.0
QR version
2.1
Scientific status
Established
Documentation status
Documented
Clinical status
Documented — cutaneous topical composition, no therapeutic claim
Approval status
Approved
Last revision
2026-02
Responsible institute
SIRIAM LAB — European institute for neurodermal science
Responsible author
SIRIAM LAB documentation team
Scientific reviewer
Scientific review board
Current language
English (EN)
Additional languages
Product identifier
SIR-OAA-01
Executive summary
The reading entry of the record: what the composition is for, in professional and in patient language.
Purpose
OAA DUO exists to give practitioners a clearly delimited application field at the occipital transition, with a two-step texture sequence that supports consistent, reproducible routines.
Clinical goal
Primary anatomical region
occipital
Primary therapeutic objective
Documented cutaneous topical composition for the suboccipital, retroauricular, submandibular and pre-SCM application field.
Professional summary
OAA DUO is documented as a cutaneous topical composition for the head application field. This summary is maintained by the documentation team and updated with each revision of the record.
Patient summary
Occipital and upper cervical application zones, formulated for the cranial dermatome transition.
Keywords
Anatomical record
Anatomy is held once in the Neuro Atlas. This section declares which atlas objects the record belongs to.
Primary region
head
Body region
occipital
Dermatomes
Peripheral nerves
Plexus
Metameres
Neurocutaneous territories
Embryological layer
Related regions
Future EMG mapping
Future SRST mapping
Future atlas reference
Clinical record
The documented boundaries of the record. Statements are descriptive; no therapeutic effect is claimed.
Clinical objective
OAA DUO exists to give practitioners a clearly delimited application field at the occipital transition, with a two-step texture sequence that supports consistent, reproducible routines.
Primary indications
Secondary indications
Contraindications
Not applied to broken, irritated or recently treated skin, nor to the eye region. Documented per session by the treating professional.
Warnings
Cutaneous topical composition. Information is provided for education and professional reference; it is not medical advice and implies no therapeutic effect.
Expected response
Sensory and cutaneous topical observations only, recorded in the professional log so successive periods remain comparable.
Treatment phase
Evidence status
Professional notes
Patient notes
Application record
The reproducible application of the record: field, sequence, cadence and handling.
Application zone
Application method
Treatment frequency
Week 1–2 · 1–2 applications per day
Treatment duration
Until phase 2 is introduced
Maintenance
The sequence is continued at a reduced cadence. Frequency, zones and observations are recorded in the professional log sheet and reviewed at agreed intervals.
Patient instructions
Professional instructions
Storage
Stored closed, upright and away from direct sunlight. Storage conditions are documented on the label and repeated here without alteration.
Shelf-life
Packaging
DUO presentation; batch OAA-2602.
Formulation record
The current formula is read-only. A proposed successor is held alongside it and never merged into it.
Formulation philosophy
The record is built around one field and two textures. Phase 1 carries the aromatic, lipid-affine fraction and is applied first across the four official zones; phase 2 is a lighter aqueous texture applied over the identical zones to close the sequence. Splitting the composition in two keeps each texture simple, makes the sequence reproducible between practitioners, and lets the same field be documented step by step. The record documents composition and application only; no physiological or therapeutic mechanism is claimed.
Scientific rationale
The occipital field is supplied predominantly by the dorsal ramus of C2 and by C2–C3 contributions travelling with the lesser occipital nerve. This convergence of cranial and cervical territories makes the region anatomically distinctive and well suited to a dedicated surface concept.
Current formula
2.1 — Reference composition of the flagship record.
Mechanism
The record is built around one field and two textures. Phase 1 carries the aromatic, lipid-affine fraction and is applied first across the four official zones; phase 2 is a lighter aqueous texture applied over the identical zones to close the sequence. Splitting the composition in two keeps each texture simple, makes the sequence reproducible between practitioners, and lets the same field be documented step by step. The record documents composition and application only; no physiological or therapeutic mechanism is claimed.
Manufacturing notes
Quality notes
Current PF
PF-OAA-2.1
Current formula version
2.1
Future formula
2.2 — Revised emollient fraction proposed for the phase 2 texture; held alongside version 2.1.
Future change request
Under review, revision 2026-05
Ingredient table
| Constituent | Role | Purpose | Category |
|---|---|---|---|
| Aqua base | Carrier phase | Sets the water phase that determines spreadability across a defined surface field. | Carrier system |
| Glycerin | Moisture binding | Keeps the applied layer supple so the same field can be worked repeatedly without dryness on the skin surface. | Humectant |
| Shea butter | Skin-feel and occlusive body | Gives the texture enough body to stay on the applied zone rather than running along the hairline. | Emollient |
| Panthenol | Surface conditioning | Documented as a conditioning constituent of the cutaneous topical base; contributes to a smooth, non-tacky finish. | Conditioning agent |
| Tocopherol | Formulation stability | Protects the lipid fraction over the shelf life of the record so successive batches stay comparable. | Antioxidant stabiliser |
| MSM | Documented constituent of both phases | Documented constituent of phase 1 and phase 2 of the OAA record; kept at a low level so the texture of both steps stays light and spreadable. | Sulphur constituent |
| Rosemary leaf extract | Aromatic and antioxidant fraction | Gives phase 1 its recognisable aromatic signature, which practitioners use to distinguish the two textures during a session. | Botanical extract |
| Magnesium chloride | Water-phase mineral constituent | Documented constituent of the phase 2 water phase; contributes to the lighter, faster-absorbing texture of the integration step. | Mineral salt |
Current → proposed
| Field | Current | Proposed |
|---|---|---|
| Version | 2.1 | 2.2 |
| Status | Approved | Under review |
| Revision | 2026-02 | 2026-05 |
| Summary | Reference composition of the flagship record. | Revised emollient fraction proposed for the phase 2 texture; held alongside version 2.1. |
Documentation record
Each document exists once in the controlled set and is referenced from here; nothing is duplicated.
Product formula
PF-OAA-2.1
Reference manuals
Standard operating procedures
Appendices
Handbook chapters
Part IV — Formulation records · OAA DUO record
Downloads
Scientific references
QR information
/products/oaa-duo
Version history
Connected knowledge
The record as a node of the knowledge network. Relationships are declared here and resolved by the graph.
Related products
Related anatomical structures
Related dermatomes
Related peripheral nerves
Related plexuses
Related ingredients
Related publications
Related research
Related RM
Related SOP
Future clinical cases
Future AI suggestions
QR record
The product page is the official destination of every QR code printed on the packaging.
QR status
Active
QR version
2.1
QR URL
/products/oaa-duo
QR created
2026
QR last updated
2026-02
Current batch
OAA-2602
Current product version
2.1
Patient information
Essential reading describes what the composition is, where it is applied and in which order, without clinical interpretation.
Professional information
Professional reading opens the complete monograph: anatomy, composition architecture, protocol and revision record.
Version record
The current version is never overwritten. Every superseded version is archived and retained.
Current version
2.1
Previous version
None recorded
Next planned version
2.2
Revision date
2026-02
Change requests
2.2 — Under review
Approval workflow
Current → proposed → scientific review → approval → publication → archive.
Archive
1 documented version retained.
Archive
| Version | Date | Change |
|---|---|---|
| 1.0 | 2026 | Initial documentation record published in the Product Library. |
Search metadata
The flat index of the record, prepared for platform search and future APIs.
Region
Dermatomes
Peripheral nerves
Plexus
Metamers
Clinical goal
Ingredients
Therapeutic category
Product family
Current version
Documentation
Research
Digital relationships
- PFProduct formula card PF-OAA-2.1In preparationOne formula card per version; referenced, never duplicated.
- RM-001Ingredient libraryReservedSingle source for every constituent used in a formulation.
- RM-002Formula matrixReservedComposition matrix across families and versions.
- RM-003Approved materialsReservedQualified raw materials and their specifications.
- RM-004InventoryReservedMaterial positions, lots and expiry tracking.
- RM-005ManufacturingReservedProcess documentation and manufacturing instructions.
- RM-006Quality assuranceReservedRelease checks, deviations and corrective actions.
- RM-007EquipmentReservedEquipment identity, qualification and maintenance.
- RM-008Change controlReservedGovernance of proposed versions and their approval.
- RM-009StabilityReservedStability programme and observation intervals.
- RM-010Clinical outcomesReservedStructured observation framework for practitioners.
- SOP-01Application documentationPublishedProcedure referenced by this record.
- SOP-02Record revision and approvalIn preparationProcedure referenced by this record.
- Appendix ATerminologyPublishedControlled appendix of the documentation set.
- Appendix BIdentifiers and codesPublishedControlled appendix of the documentation set.
- ATLASNeuro AtlasPublishedAnatomical objects of this record.
- HANDBOOKPart IV — Formulation recordsPublishedHandbook placement of this record.
- QRQR resourcePublishedOfficial destination of the printed QR code.
- PUBScientific publicationsReservedPublications citing this record.
Chapter 12
Knowledge graph
This record as a node of the knowledge network: products, anatomy, atlas structures, ingredients and documents.
This record as a node of the knowledge network: related products, anatomy, research, handbook parts and documents.
Documentation metadata+
Chapter 12 — related anatomy
Related documents
Future references
- AI suggestionsReservedAutomatically generated relationship proposals reviewed before publication.
- Clinical casesReservedCase records connected to this formulation.
Research
Related research modules
Chapter 13
Version history
Current version, previous versions, change requests, scientific review, approval, publication and archive.
Version control of the record: current version, previous versions, change requests, review, approval, publication and archive.
Documentation metadata+
Chapter 13 — related anatomy
Declared; content in preparation.
Related documents
Future references
- ArchiveReservedImmutable archive of superseded versions.
Record
Version history
- v1.0 · 2026Initial documentation record published in the Product Library.
Version record
The current version is never overwritten. Every superseded version is archived and retained.
Current version
2.1
Previous version
None recorded
Next planned version
2.2
Revision date
2026-02
Change requests
2.2 — Under review
Approval workflow
Current → proposed → scientific review → approval → publication → archive.
Archive
1 documented version retained.
Archive
| Version | Date | Change |
|---|---|---|
| 1.0 | 2026 | Initial documentation record published in the Product Library. |
Version lifecycle
- 01Current versionApproved and published; read-only.Published
- 02Proposed versionHeld alongside the current version, never merged into it.In preparation
- 03Scientific reviewReview of the proposal against the reference manuals.Reserved
- 04ApprovalFormal approval by the scientific reviewer.Reserved
- 05PublicationThe approved version becomes the current version.Reserved
- 06ArchiveThe superseded version is retained for traceability.Reserved
The current version is never overwritten. A proposed version is held as a separate object; superseded versions are archived and retained.
Chapter 14
Appendices
Supplier list, ingredient classification, document coding, QR standard and glossary.
Supporting registers of the handbook: suppliers, ingredient classification, document coding, the QR standard and the glossary.
Documentation metadata+
Chapter 14 — related anatomy
Declared; content in preparation.
Related documents
Future references
- Supplier qualificationReservedQualification status per supplier, held in RM-003.
Appendix A — Supplier list
| Supplier | Referenced by |
|---|---|
| Vitals | OAA-1 |
| Matisson | OAA-1 · OAA-2 |
| WeightWorld | OAA-1 |
| Aroma Zone | OAA-1 |
| Soria Natural | OAA-1 |
| NH | OAA-2 |
Appendix B — Ingredient classification
- Base
- Carrier phase determining spreadability and dermal contact time.
- Functional
- Constituent selected for the documented functional intent of the phase.
- Modulating
- Constituent adjusting tolerance, texture or release of the phase.
- Sensory
- Constituent determining the sensory signature of the application.
Appendix C — Document coding
- HB-…
- Handbook chapter — the scientific master.
- SDR-…
- SIRIAM digital record — the digital product record.
- PF-…
- Product formula — the formulation master.
- SOP-…
- Standard operating procedure — the manufacturing master.
- RM-…
- Reference manual — the quality management master.
Appendix D — QR standard
- Source
- Patient information is generated from the digital record; it is never written separately.
- Scope
- Product identity, treatment goal, timeline, application areas, safety and quality assurance.
- Binding
- Each published QR surface is bound to one approved record version.
Appendix E — Glossary
- Neurodermal
- The relationship between segmental innervation and the cutaneous surface.
- DUO
- A sequential formulation applied in two documented phases.
- Metamere
- The segmental unit linking dermatome, myotome, sclerotome and viscerotome.
- SRST
- Segmental reflex surface topography.
Quality system
Version control
The current composition and any proposed successor are documented side by side. Approval and change control are handled outside the platform.
Current formula
- Version
- 2.1
- Revision date
- 2026-02
Reference composition of the flagship record.
Proposed formula
- Version
- 2.2
- Revision date
- 2026-05
Revised emollient fraction proposed for the phase 2 texture; held alongside version 2.1.
QR information
- QR target
- /products/oaa-duo
- Batch reference
- OAA-2602
- Record status
- Documented
The QR code printed on the label resolves to this record. The product page is the single source of truth; printed material never carries content that is not documented here.
Controlled documents →Continue
Explore further
Cutaneous topical formulation. Information is provided for education and professional reference; it is not medical advice and implies no therapeutic effect.
Back to the ecosystem →Knowledge graph
Related knowledge
Everything connected to this formulation: anatomy, application zones, ingredients, protocols, research and documentation.
Formulation
Metamer
Peripheral nerve
Neurocutaneous zone
Application zone
Knowledge article
Research
Download